A Model of Breast Cancer Micrometastasis in a Three-Dimensional (3D) Liver Spheroid for Testing an Antimetastatic Therapy

构建三维(3D)肝球体中乳腺癌微转移模型以测试抗转移疗法

阅读:10
作者:Kseniya V Nevskaya ,Alexandra G Pershina ,Lina V Efimova ,Ekaterina V Sukhinina ,Polina K Kozlova ,Alina Yu Ryzhkova ,Ekaterina S Hmelevskaya ,Marina K Ibragimova ,Irina A Tsydenova ,Nikolai V Litviakov ,Elena V Udut

Abstract

Even though the survival and proliferation stages of cancer cells that have newly settled at a metastatic site are the rate-limiting stages and the most promising targets for drugs, there is a lack of models of the earliest stage of metastasis formation. A method for modeling breast cancer liver metastasis is described here: a stage of transition of a differentiated tumor cell into a cell actively proliferating in a three-dimensional (3D) liver spheroid. Opposite to existing heterocellular 3D models of metastases, the protocol allows modeling the initial stage of liver colonization by metastatic cells, the so-called "micrometastases." The method includes obtaining a line of fluorescent tumor cells, fluorescence-activated sorting of differentiated cells, preparing a single-cell suspension of liver cells, forming a liver spheroid in an agarose mold, inducing the tumor cell dedifferentiation and proliferation using IL-6, and intravital microscopy of spheroids, with subsequent processing and analysis of fluorescent images in the ImageJ software. The performance of the proposed model was demonstrated using microRNA therapeutics. The ability of a combination of microRNAs to suppress the transition of micrometastasis to macrometastasis in the 3D liver spheroid was confirmed by an immunofluorescent assay of spheroid sections and transcriptome analysis. Key features • The method introduces a 3D model of liver micrometastasis formation using differentiated tumor cells. • The 3D spheroid consists of all the main types of normal liver cells and better reproduces the microenvironment. • The method allows one to evaluate the effectiveness of a drug that blocks the transition of micrometastases to macrometastases. • The model is optimal for studying RNA-based therapeutic agents, as well as prodrugs that require metabolism in the liver for activation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。